

Frequency of Dyslipidemia in Patients with Lichen Planus: A Comparative Cross-Sectional Study

Sana Khan, Muhammad Suleman Pirzado, Hafiz Bashir Ahmed Kalhoro, Nadia Rajper,
Sikander Munir Memon, Faryal Hussain Memon

\$ % 6 7 5 \$ & 7

& 21&/86,217KLV VWXG\ FRQFOXGHG WKDW WKH IUHTXHQF\ RI G\VOLSLG
SDWLHQWV FRPSDUHG WR KHDOWK\ LQGLYLGXDOV
.(<:25'6 /LFKHQ 3ODQXV &KROHVWHURO '\VOLSLGHPLD 'HUPDWRORJ\

This article may be cited as: Khan S, Pizzado MS, Kalrao HBA, Rajer N, Memon SM, Memon FH. Frequency of Dyslipidemia in Patients with Lichen Planus: A Comparative Cross-Sectional Study. J Liaquat Univ Med Health Sci. 2022;21(02): 121-5
doi: 10.2442/jlums.2021.00826 Enub 2021 May 08

, 1752 '8 & 7, 21

Lichen planus (LP) is an autoimmune disease of chronic inflammation that affects the face, mouth, genital mucosa, scalp and nails. Six P's (planar; purple, polygonal, pruitus, papules and plaques) are used to identify LP lesions. Generally, the presentation is acute, and the flexor surfaces of wrists, forearms and legs are affected. Often the lesions show lacy, reticular, white lines called Wickham striae¹. The exact cause of LP is not very clearly understood. It was found to be an immunologically mediated disease, and some triggers are clinically found to be responsible for it. There are obvious links with the factors, such as drugs, stress, environmental allergens, food allergens and systemic illness.

Dyslipidemias are disorders of lipoprotein metabolism, including the overproduction and deficiency of lipoproteins. Many dermatological disorders are known to be associated with dyslipidemia. Most of these are chronic inflammatory diseases, and the underlying mechanism may involve the secretion of proinflammatory cytokines. Studies have shown an

increased frequency of dyslipidemia in skin disorders such as psoriasis, lichen planus, pemphigus, granuloma annulare, histiocytosis, and connective tissue disorders such as lupus erythematosus. It was established that lichen planus was associated with dyslipidemia²³. Chronic inflammation can explain the association with dyslipidemia in patients with lichen planus. Studies have reported that individuals with lichen planus have significantly higher levels of various lipids compared to the control group.⁴ Santiago AS et al¹¹ revealed the higher dyslipidemia prevalence in lichen planus patients relative to the cases group ie 61.3% vs 32.5%.

Epidelial cells in IP have demonstrated enzyme defects as well as impaired expression of the carbohydrate. Among patients living with IP, there was an increased incidence of diabetes and resistance to carbohydrates, indicating their possible role in the pathogenesis⁴. Oral LP was also diabetes-related^{5,6}. However, not all research found similar results: the prevalence of systemic diseases such as hypertension (21%), arthritis (14%) and diabetes (5%) was not higher than projected in the general population in a single report⁷. Very few studies investigated the connection between IP and dyslipidemia to our knowledge.

Received: 26-11-2020
Revised: 20-04-2021
Accepted: 21-04-2021
Published Online: 08-05-2021

It may help screen lipid levels in men or women with lichen planus in detecting people at risk to launch preventive therapy against cardiovascular disease²⁸. The study's objective was to determine the relationship of lichen planus (LP) with dyslipidemia. The rationale for this study was to assess the association between lichen planus and dyslipidemia in our local population. Although its association was already known, very few local studies on this subject have been found in our setting; this study will provide local statistics on the problem and be a valuable addition to existing literature. Also, based on these results, the high-risk patients can be given special attention. A proper screening protocol can be designed to screen lipid levels in lichen planus patients, which will help the clinicians make many concrete considerations in our guidelines for routine practice, treating dyslipidemia in these particular patients to reduce their morbidity and cardiovascular diseases.

$0(7+2'2/2^* <$

It was a comparative cross-sectional study conducted at the department of dermatology, Liaquat University of Medical & Health Sciences, Hyderabad, from October 2016 to April 2017. The calculated sample size was 100, i.e., 50 in each group with a 95% confidence level, 80% power of the study, taking a percentage of dyslipidemia in the A group as 61.3% and in the B group as 32.5%.⁹ Non-probability, consecutive sampling was used. The ethical approval was taken from the College of Physicians & Surgeons of Pakistan. All patients with cutaneous lichen planus of more than one month duration, both genders aged between 20–50 years were included in the study. The exclusion criteria for the study were patients with oral lichen planus (lichen planus in the oral cavity), pregnancy and lactation (urine pregnancy test for women of childbearing age), patients with psoriasis (assessed on clinical examination, i.e., chronic erythematous scaly plaques (raised areas of inflamed skin covered with silvery-white scaly skin)), hepatitis and chronic liver disease (assessed on history and s/bilirubin higher than 1.0mg/dL), renal disease (renal function test, creatinine higher than 1.1mg/dL), the lichenoid reaction caused by some drug or dental amalgam (history of drug intake before the appearance of lesion or any dental procedure) and patients not willing to be included in the study.

Written informed consent from the patients was obtained. Fifty subjects who were presented to the department of dermatology, Liaquat University of Medical & Health Sciences, Hyderabad, fulfilling the inclusion criteria and 50 attendants of the patients that were similar in demographic characteristics, i.e., age, gender, height, weight, BMI and socioeconomic status, were selected.

Each patient's blood sample (after 8 hours of fasting)

was collected and sent to the LLMHS diagnostic and research laboratory for lipid profile (elevated total cholesterol higher than 200mg/dL and elevated LDL-C higher than 130mg/dL in LP patients). Where a consultant pathologist prepared each report (at least three years of post fellowship experience), and the presence or absence of dyslipidemia was noted. All of these data have been recorded on a specially designed proforma.

Statistical analysis was carried out using version 22.0 of SPSS. Results for quantitative variables, i.e., age, period of disease and index of body mass (BMI), were reported as mean and standard deviation. For qualitative variables such as gender, diabetes, hypertension, obesity and dyslipidemia (Present/Absent), frequency and percentage were measured. Effect modifiers such as age, disease duration, gender, diabetes mellitus (Yes/No), hypertension (Yes/No), and obesity (Yes/No) have been controlled by stratification and post-stratification. Chi-square was applied to determine their effect on outcome, and P-value less than or equal 0.05 was considered significant. The adjusted odds ratio was also calculated.

5(68/76

The age range in this study was 31.23±7.27 years, from 20–50 years of age. The mean age of A-group patients was 30.76±6.87 years, and 31.72±7.69 years in B-group. Subjects aged between 20 and 50 years. Of 100 patients, 51(51.0%) were males and 49 (49.0%) were females (7 D E O.H). The mean disease period was 4.33±2.08 months. The mean BMI was 29.54±4.41 kg/m².

Dyslipidemia in A-group was seen in 35 (70.0%) patients. 18 (36.0%) patients were seen in the B-group. Stratification of age-related dyslipidemia was shown in 7 D E O.H. This result showed significant variations in dyslipidemia between the two groups of 20 and 35 years of age.

Dyslipidemia stratification concerning disease duration is shown in 7 D E O.H. Dyslipidemia stratification for diabetes mellitus, obesity (BM), and hypertension have been displayed in 7 D E O.H , 9

7 \$ % / (, ' , 675 , % 18 Z) 23 \$ 7 , (17 6
\$ & 25 ' , 1 * 72 ' < 6 / , 3 , ' (0 , \$, 1 % 27 + * 52836

	\$ JURXS		Q %JURXS	
	No of Patients	%	No of Patients	%
'\VOLSLGHPLD	Yes 35	700	18	360
	No 15	300	32	640
2 E H V L W \	Yes 23	460	25	500
	No 27	540	25	500
+ 7 1	Yes 20	400	18	360
	No 30	600	32	640

The P-value is statistically significant at 0.001.

The odds ratio is statistically significant at 4.148.

7 \$ % / (, , 6 7 5 \$ 77,) 2& \$ 2) \$ -* 5 (/ \$ 7 (' < 6 / , 3 , ' (0 , \$	\$ J H R I \$ * URXS Q % JURXS Q 3 SDWLH Q'WMOLSLGHPL'DVOLSLGHPL'DOXH \HDUV
	Yes no yes no
28 07 11 21	(800%) (200%) (34.38%) (65.62%)
07 08 07 11	(46.67%) (53.33%) (38.89%) (61.11%)
	* HQ GHU
0 DOH 17 06 10 18	(73.91%) (26.09%) (35.71%) (64.29%)
) HPDOH 18 09 08 14	(66.67%) (33.33%) (36.36%) (63.63%)
7 \$ % / (, , , ' < 6 / , 0, \$ (6 7 5 \$ 7 ,) , & \$ 7 , 2 1 & 2 1 & (5 1 , 1 * 7 + (' 8 5 \$ 7 2) 7 + (' , 6 (\$ 6 (
' XUDWLFQ \$ * URXS Q % JURXS Q RI GLVHD'WMOLSLGHPL'DVOLSLGHPL'DOXH PRQWKV	3 YDOXH
	yes no yes no
" PRQWKV 26 08 10 23	(76.47%) (23.53%) (30.30%) (69.70%)
! PRQWKV 09 07 08 09	(56.25%) (43.75%) (47.08%) (52.92%)
7 \$ % / (, 9 6 7 5 \$ 77,) 2& \$ 2) ' < 6 / , 3 , ' (0 , \$ & 2 1 & (5 1 , 1 * ' , \$ % (7 0 (6 / , 7 8 6	
\$ * URXS Q % JURXS Q 'LDEHWHV VOLSLGHPL'DVOLSLGHPL'DOXH PHOOLWXV	3 YDOXH
	yes no yes no
< HV 16 05 11 14	(76.19%) (23.81%) (44.10%) (56.0%)
1 R 19 10 07 18	(65.52%) (34.48%) (28.0%) (72.0%)
	+ \SHUWHQVLRQ
< HV 11 07 07 13	(61.11%) (31.89%) (35.0%) (65.0%)
1 R 24 08 11 19	(75.0%) (25.0%) (36.67%) (63.33%)
	2 EHVLWI
< HV 16 07 11 14	(69.57%) (30.43%) (44.10%) (56.0%)
1 R 19 08 07 18	(70.37%) (29.63%) (28.0%) (72.0%)

' , 6 & 8 6 6 , 2 1

In some skin diseases, such as androgenetic alopecia^{4,10}, psoriasis, cardiovascular risk factors have been measured^{11,12}. Although lipid abnormalities have been studied in IP, comparative cross-control studies on metabolic syndrome components in IP are limited.

Some studies in cases of IP proved this association, as inflammation triggers lipid metabolism disorders such as increased serum triglycerides (TG) or lower lipoprotein cholesterol (HDL-C) levels. Such lipid disorders associated with chronic inflammation lead to an increase in the risk of cardiovascular dyslipidemia. Chronic inflammation may be associated with dyslipidemia in IP patients. Lipid level screening may be helpful for men or women with IP to detect people at risk and initiate preventive treatment against cardiovascular disease development¹³. Santiago SA et al¹¹ reveal the higher Dyslipidemia prevalence in lichen planus patients compared to the B group, i.e. 61.3% vs 32.5%.

Twenty-eight cases were males in another study¹⁵, and 22 cases were females. Patient ages ranged between 19 years and 78 years. The mean age was 41.71 for IP males and 40.64 for lichen planus females. In patients with IP, the frequency of dyslipidemia was 38% in cases and 6% in controls¹⁵. Panchal F 2015¹⁷ observed statistically significantly higher levels of TC, TG, and LDL-C and a decline in HDL-C levels in IP patients relative to their controls.

In a study, the prevalence of abnormally elevated total cholesterol (>200mg/dl) was significantly elevated in IP patients vs healthy controls (53% of IP and 15% of control) ($\chi^2 = 8.32$, $p < 0.05$) and the prevalence of abnormally elevated LDL-C (>130mg/dl) was highly significantly elevated in IP patients vs healthy controls (86.7% of IP and 10% of control) ($\chi^2 = 42.92$, $p < 0.001$)¹⁷.

A mean total cholesterol level of normal healthy control in Pakistan is reported as 190.06 mg/dL²⁰. The total cholesterol level in Europe's whole population is 210.82 mg/dL¹⁹. Oral mucosal IP is more associated with dyslipidemia²⁰, and metabolic syndrome is mainly associated with the oral type of IP. At the same time, triglyceride is significantly associated with hypertrophic IP but also showed an increase in other lipid profile parameters but not significant²¹.

Various pathways clarified the link between inflammation and dyslipidemia. Modulating lipoprotein lipase (LPL) enzymatic activity by anti-LPL antibodies and decreased LPL activity due to various pro-inflammatory cytokines such as tumor necrosis factor, interleukin 1, interleukin 6, and monocyte protein 1 and interferon chemo attractant. In addition, atherogenic autoantibodies complexes to oxidize LDL and oxidized anti-cardiolipin are generated in response to inflammatory oxidation. It increases LDL deposition in the endothelial wall²².

The clinical study of plasma lipids in patients with IP should be conducted not only for diagnosis and treatment but also for prevention, considering that atherosclerotic lesions begin to occur at an early age and intensify in the presence of other risk factors. To set priorities for intervention in dyslipidemia patients the risk of CV must be stratified. Dyslipidemia and

other risk factors such as kidney diseases, diabetes, smoking and arterial hypertension are common and significantly enhance CV events. Initiatives to establish evidence to support the hypothesis of dyslipidemia in patients with LP could lead to the possibility of assessing CV risk²³.

& 21 & / 86 , 21

This study concluded that the frequency of dyslipidemia is higher in lichen planus patients compared to the healthy group

(WKLFD O SHUP College R& Physicians & Surgeons Pakistan REU permission letter No CPSP/REU/DER-2015/164/502, dated 23/6/2018

& R QIOLFW RI There is no conflict of interest among the authors

) X Q G t This is a self-funding project

'DWD 6KDULQJ 6TWDWHU Supporting this study's findings are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions

\$ 87 + 25 & 2175 , % 87 , 216

KhanS: Concept and design

PizzadoMS: Data interpretation, drafting of the article

KalhoonHFA: Intellectual content

RajparN: Collection and assembly of data

MemonSM: Analysis, Statistical expertise

MemonFH: Final Proofreading

5() (5(1 & (6

- Alashdan MS, Cirillo N, McCullough M. Oral lichen planus: a literature review and update. *Arch Dermatol Res.* 2016; 308(8): 539-51. doi: 10.1007/s00403-016-1657-2
- Shataf A, Zaki NS, Kady D, Rashed I, Awad MA. Levels of osteopontin in plasma and tissue in relation to metabolic status in patients with lichen planus. *J Egypt Womens Dermatologic Soc.* 2017; 14(3): 173-8. doi: 10.1097/OLW.0000000000000526
- Garcia-Pola MI, Llorente-Pendás S, Secoane Romeo JM, Berasaluce MI, García-Martín JM. Thyroid Disease and Oral Lichen Planus as Comorbidity: A Prospective Case Control Study. *Dermatology.* 2016; 232(2): 214-9. doi: 10.1159/000424388
- Powell SM, Ellis JP, Ryan TJ, Vickery HR. Glucose tolerance in lichen planus. *Br J Dermatol.* 1974; 91(1): 73-5. doi: 10.1111/j.1365-2133.1974.tb6719x
- Tavangar A, Ghalehjani P, Baroujeni M, Ghoeishian F. Salivary levels of interleukin-8 in oral lichen planus and diabetic patients: A biochemical study. *Dent Res J (Isfahan).* 2017; 14(3): 209-14. doi: 10.4103/1735-3327.208771.
- Mogado Canasco D, Corbalán A, Fusté Novell

X, Mascaño Jr J, Iriarte P. Aggressive erosive lichen planus associated with hepatitis C responding to sofosbuvir/ledipasvir treatment. *Indian J Dermatol Venereol Leprol.* 2019; 85(3): 326-9. doi: 10.4103/ijdl.ijdl_225_18

- Kaontongklangit R, Daoorpan P, Tantanapornkul W, Palasuk J. Clinical profile of 102 patients with oral lichen planus in Thailand. *J Clin Exp Dent.* 2019; 11(7): e625-e629. doi: 10.4317/jced.55814
- Shenoy C, Shenoy M, Rao G. Dyslipidemia in dermatological disorders. *N Am J Med Sci.* 2015; 7(10): 421-428. doi: 10.4103/1947-2714.168657
- Arias Santiago S, Buendía-Eisman A, Aneiros-Fernández J, Gómez-Prieto MS, Gutiérrez-Salmerón MI, García-Mellado V et al. Lipid levels in patients with lichen planus: a case-control study. *J Eur Acad Dermatol Venereol.* 2011; 25(12): 1398-401. doi: 10.1111/j.1468-3083.2011.08983.x
- Kar BR, Parida M, Patra N. Metabolic derangements in lichen planus - A case control study. *J Clin Diagnostic Res.* 2016; 10(11): WC01-WC08. doi: 10.7860/JCDR/2016/21998.8818
- Diop A, Ly F, Ndiaye MT, Seck B, El Omani A, Diouf A et al. Epidemiology, clinical features, and associated factors in 78 cases of lichen planus on black skin. *Int J Dermatol.* 2020; 59(2): 137-42. doi: 10.1111/ijd.14698
- Otero Rey EM, Yáñez-Busto A, Rosa Heniques IF, López-López J, Blanco-Carrón A. Lichen planus and diabetes mellitus: Systematic review and meta-analysis. *Oral Dis.* 2019; 25(5): 1253-64. doi: 10.1111/odi.12977
- Balasubramaniam P, Ogholi M, Moss C. Lichen planus in children: review of 26 cases. *Clin Exp Dermatol.* 2008; 33(4): 457-9. doi: 10.1111/j.1365-2230.2008.02694.x
- Ozlu E, Karadag AS, Toprak AE, Uzuncakmak TK, Gerin F, Aksu F et al. Evaluation of Cardiovascular Risk Factors, Haematological and Biochemical Parameters, and Serum Endocan Levels in Patients with Lichen Planus. *Dermatology.* 2016; 232(4): 438-43. doi: 10.1159/000447587
- Panchal F, Ray S, Munshi R, Bhalerao S, Nayak C. Alterations in lipid metabolism and antioxidant status in lichen planus. *Indian J Dermatol.* 2015; 60(5): 439-444. doi: 10.4103/0019-5154.159624
- Bakr HG, Eldesouky F, Esawy AM, El-Alawi SM. Assessment of Dyslipidemia and Other Cardiovascular Risk Factors in Patients With Mycosis Fungoides and Lichen Planus. *Int J Sci Res.* 2016; 5(8): 726
- Santos VGF, Betuzzi R, Fianchini E, Silva Cavalcante Marcos David da, Kiss Maria Augusta peduti da molin, Lima-Silva AE. Relationship Between Attack and Pause in World Taekwondo Championship Contests: Effects of Gender and

- Weight Category Muscles Ligaments Tendons J 2014; 4(2): 127-31.**
- 18** Harif S, Akhtar B, Afzal MN Serum Lipoprotein (a) levels in acute coronary syndrome: Comparison of younger and elderly patients with healthy controls. *Pak J Med Sci* 2019; 35(6): 1718-23 doi: 10.1289/pjms.356377.
- 19** Redon P, Maloberti A, Facchetti R, Redon J, Lube E, Bonelli M et al Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries: findings from the blood pressure control rate and cardiovascular risk profile study. *J Hypertens*. 2019; 37(2): 380-8 doi: 10.1097/HJH.0000000000001908
- 20** Ying J, Xiang W, Qiu Y, Zeng X Risk of metabolic syndrome in patients with lichen planus: A systematic review and meta-analysis. *Nadone B, editor: PLoS One*. 2020; 15(8): e0238005
- 21** Lai YC, Yew YW, Schwartz RA Lichen planus and dyslipidemia: a systematic review and meta-analysis of observational studies. *Int J Dermatol* 2016; 55(5): e295-304 doi: 10.1111/ijd.13234
- 22** Vinken Shuster M, Gendelman O, Tiosano S, Comaneshter D, Cohen AD, Amital H Ischemic heart disease and ankylosing spondylitis: assessing the role of inflammation. *Clin Rheumatol* 2018; 37(4): 1053-8 doi: 10.1007/s10067-018-4087-y
- 23** Schwingenschlögl I, Stassner B, Hoffmann G Effects of Monounsaturated Fatty Acids on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis. *Ann Nutr Metab* 2011; 59(2-4): 176-86 doi: 10.1159/00034071.



AUTHOR AFFILIATION:

Dr. Sana Khan

Department of Dermatology
Liaquat University of Medical & Health Sciences
(LUMHS), Jamshoro, Sindh Pakistan.

Dr. Muhammad Suleman Pirzado

Assistant Professor
Department of Molecular Biology and Genetics Laboratory
LUMHS, Jamshoro, Sindh Pakistan.

Dr. Hafiz Bashir Ahmed Kalhoro

Assistant Professor
Department of Dermatology
LUMHS, Jamshoro, Sindh Pakistan.

Dr. Nadia Rajper

Department of Dermatology
LUMHS, Jamshoro, Sindh Pakistan.

Dr. Sikander Munir Memon (Corresponding Author)

Research Officer, Medical Research Center
LUMHS, Jamshoro, Sindh Pakistan.
Email: drsikandermemon@gmail.com

Dr. Faryal Hussain Memon

Department of Dermatology
LUMHS, Jamshoro, Sindh Pakistan.



2022© This is an Open Access article distributed under the terms of the Creative Commons Attribution – Non-Commercial 4.0 International License, which permits unrestricted use, distribution & reproduction in any medium provided that the original work is cited properly.